Rating Change
Cantor Fitzgerald reiterated its Overweight rating on Eli Lilly and Company (NYSE:LLY) on October 08, 2026.
reiterateNYSE:LLY
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly and Company (LLY)
Cantor Fitzgerald reiterated its Overweight rating on Eli Lilly and Company (NYSE:LLY) on October 08, 2026.
At publication ·
What changed
Eli Lilly and Company (NYSE:LLY) · reiterate
- Firm
- Cantor Fitzgerald
- Rating
- Overweight to Overweight
- Price at event
- $1,169.93
- Market capitalization
- $906.5B
At a glance
Key takeaways
- Eli Lilly trades at $1,169.93 with a $906.5B market capitalization and gained 9.1% over the past 52 weeks.
- Among the 10 most recent analyst ratings, 9 are Buy, 0 are Hold, and 1 is Sell, indicating strong bullish consensus.
- Cantor Fitzgerald reiterated an Overweight rating on October 8, 2026, consistent with recent positive ratings from Morgan Stanley and JP Morgan.
- Analyst consensus recommendations alone have mixed predictive power, but significant changes in consensus can be more meaningful signals.
Market Context
Eli Lilly and Company operates in the Healthcare sector. The stock currently trades at $1169.93 with a market capitalization of $906.5B. The stock has gained 9.1% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eli Lilly and Company.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Eli Lilly and Company
Among the 10 most recent ratings: 9 Buy, 0 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 08, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Oct 07, 2026 | Morgan Stanley | Overweight | N/A |
| Sep 28, 2026 | JP Morgan | Overweight | N/A |
| Sep 22, 2026 | TD Cowen | Buy | N/A |
| Sep 18, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LLY Stock Page
Frequently Asked Questions
What does the Overweight rating mean for LLY?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Eli Lilly and Company (NYSE:LLY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LLY forecast page.
Loading related coverage…
